Arena Pharmaceuticals, Inc. stock price

Arena Pharmaceuticals, Inc. latest news:


  • 07/11/2017 08:50:54

    Why Arena Pharmaceuticals Is Knocking It Out of the Park


  • 07/10/2017 14:23:52

    Arena Pharmaceuticals stock skyrockets on positive hypertension-drug study

    Arena Pharmaceuticals Inc. shares jumped 35% in late trading Monday after the company announced positive results from a drug study. The San Diego company said that a phase 2 study of a drug targeted at pulmonary arterial hypertension, a disease that causes high blood pressure in the lungs, showed "a statistically significant absolute change from baseline." In a study of 61 patients, those that received the drug, called ralinepag, showed 29.8% greater improvement than patients in a placebo group and 20.1% improvement compared with the baseline, the company said. Arena stock topped $25 in after-hours trading immediately following the announcement, after closing with a 4.5% decline at $18.39; Arena shares have not hit $25 in regular trading since 2015. Arena planned a conference call to discuss the results for 4:30 p.m. Eastern time Monday.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Ares Capital CorporationARCC | Argo Group International Holdings, Ltd.AGII | Argo Group International Holdings, Ltd.AGIIL | Argos Therapeutics, Inc.ARGS | ARI Network Services, Inc.ARIS | ARIAD Pharmaceuticals, Inc.ARIA | Ark Restaurants Corp.ARKR | ARM Holdings plcARMH | Arotech CorporationARTX | Arowana Inc.ARWA |